Imunon, Inc. (NASDAQ:IMNN) Stock Short Interest Report for October

Imunon, Inc. (NASDAQ:IMNN) was the recipient of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 215,645 shares, an increase of 245.8% from the October 15th total of 62,366 shares. Based on an average daily trading volume, of 144,672 shares, the days-to-cover ratio is presently 1.5 days. Approximately 4.0% of the company’s shares are short sold.

Imunon Stock Down 11.6%

Shares of NASDAQ IMNN traded down $0.08 during trading on Thursday, hitting $0.64. 2,183,534 shares of the company traded hands, compared to its average volume of 111,021. The business’s fifty day moving average is $1.19 and its 200 day moving average is $2.14. Imunon has a fifty-two week low of $0.49 and a fifty-two week high of $4.38. The firm has a market capitalization of $3.57 million, a price-to-earnings ratio of -0.17 and a beta of 2.10. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.82 and a current ratio of 1.82.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.09). Equities research analysts predict that Imunon will post -2.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

About Imunon

Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells. Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.